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The role of the venous system in the pathogenesis of inflammatory neurological/neurodegenerative diseases
remains largely unknown and underinvestigated. Aside from cerebral venous infarcts, thromboembolic events, and
cerebrovascular bleeding, several inflammatory central nervous system (CNS) diseases, such as multiple sclerosis
(MS), acute disseminated encephalomyelitis (ADEM), and optic neuritis, appear to be associated with venous
vascular dysfunction, and the neuropathologic hallmark of these diseases is a perivenous, rather than arterial, lesion.
Such findings raise fundamental questions about the nature of these diseases, such as the reasons why their
pathognomonic lesions do not develop around the arteries and what exactly are the roles of cerebral venous
inflammation in their pathogenesis. Apart from this inflammatory-based view, a new hypothesis with more focus on
the hemodynamic features of the cerebral and extracerebral venous system suggests that MS pathophysiology
might be associated with the venous system that drains the CNS. Such a hypothesis, if proven correct, opens new
therapeutic windows in MS and other neuroinflammatory diseases. Here, we present a comprehensive review of
the pathophysiology of MS, ADEM, pseudotumor cerebri, and optic neuritis, with an emphasis on the roles of
venous vascular system programming and dysfunction in their pathogenesis. We consider the fundamental
differences between arterial and venous endothelium, their dissimilar responses to inflammation, and the potential
theoretical contributions of venous insufficiency in the pathogenesis of neurovascular diseases.
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The human central nervous system (CNS) can be affec-
ted by a number of inflammatory demyelinating diseases.
This covers a wide range of clinically and neuropatho-
logically heterogeneous conditions, which share some
clinical characteristics, but possess distinguishing im-
munopathological features. Multiple sclerosis (MS) and
acute disseminated encephalomyelitis (ADEM) are two
of the most prominent of these inflammatory diseases.
Although these conditions have different root causes,
mechanisms, and courses, their underlying neuropathol-
ogies both exhibit perivenular demyelination. This strik-
ingly significant important finding points to significant
contributions by veins in these conditions, and suggests
that venous dysfunction or vein-targeted disease proces-
ses, (rather than arterial pathology or injury) contributes* Correspondence: jalexa@lsuhsc.edu
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2013to the development of these inflammatory CNS diseases.
Unlike the cerebral arterial system, the spatial organi-
zation of cerebral venous networks is more complex and
more often asymmetric, with greater structural hetero-
geneity than cerebral arterial anatomy. Consequently,
this half of the circulatory system has been far less stu-
died and understood [1].
Several reviews [2] have evaluated clinical and struc-
tural factors in venous contributions to neurologic dis-
eases. In addition to the inflammatory-based view of the
pathogenesis of these demyelinating diseases, the past
few years has witnessed the emergence of a controversial
view about MS. Could neurological disease processes
such as MS be triggered or intensified in part through
venous vascular disturbances? Although venous distur-
bances in particular have long been recognized in several
forms of neurological disease, we are only recently ap-
preciating how venous structure, programming, and re-
sponses contribute to specific features of these diseases.
The concept that neurologic disease can be influencedral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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venous system has raised intense worldwide debate
among researchers, with many investigators arguing
against its existence. Controlled, careful clinical studies
are needed to validate when and how vascular alterations
can contribute to forms of CNS injury and inflamma-
tion. Here, we provide a discussion on the potential
pathogenesis of these diseases, with emphasis on venous
endothelial dysfunction in MS, ADEM, and other forms
of neuroinflammation.
Pathophysiology of MS with emphasis on venous
dysfunction
MS is a group of immune-mediated demyelinating syn-
dromes associated with neurodegeneration in the human
CNS, which causes significant neurological disability in
largely younger adults (Noseworthy [3], Compston and
Coles [4]). MS can affect both gray and white matter in
any region of the CNS. Four distinct clinical patterns of
MS are recognized: relapsing-remitting (RRMS), primary
progressive MS (PPMS), secondary progressive MS, and
progressive relapsing MS. To date, vascular studies in
MS have investigated cerebrovascular capillary and large
vessel venous endothelial cells that are not always de-
rived from (or strictly relevant to) the CNS [5-7]. There
has been less research into the arterial and venous differ-
ences in MS. Despite these limitations, vascular contri-
butions in MS do appear to support the notion of the
vasculature being an initiating target in MS etiology and
not simply a bystander presentation of other disease
processes. Perhaps the strongest support for this is the
number of MS therapies that have been developed,
which target leukocyte binding to activated endothelial
cells, a central component of the blood-brain barrier
(BBB). Vascular abnormalities in MS also include evi-
dence of increased circulating markers of vascular in-
flammation, [8-10], which can lead to inflammatory
challenges that initiate or exacerbate CNS injury. Mag-
netic resonance imaging (MRI) studies in MS also in-
dicate longer mean blood-flow transit times, which
indicates relatively lower cerebral blood flow in MS
plaques, as well as decreased cerebral blood flow and
prolonged mean transit time in normal-appearing white
matter (NAWM). Decreases in brain blood flow increase
with age in MS, with severity and form of MS (PPMS >
RRMS) both of which may intensify ischemic injury
[2,9,11]. Importantly, in apparently NAWM, the state of
ischemia appears to occur before the appearance of
plaques [10]. It is unclear whether diminished cerebral
flow represents restricted perfusion (arterial-sided) or
outflow restriction (venous influences). Further, venous
blood exiting the cerebral veins of patients with MS in
susceptibility-weighted imaging (also known as blood
oxygen level dependent imaging) suggests lower nettissue oxygen consumption compared with controls [12],
which points to disturbances in energy metabolism.
These findings suggest an early role for vascular distur-
bances in MS, which may trigger later injury processes,
but do not specifically indicate underlying vascular de-
fects as their basis.
There are several significant differences between ven-
ous and arterial endothelial cells, which may play a role
in increased susceptibility of the venous compartment as
related to MS, ADEM, or chronic venous insufficiency
(CVI); these differences include arteriovenous program-
ming, flow shear-dependent gene expression, hemodyna-
mic effects on autacoids and venous valve organization.
Arterial versus venous differences in response to
inflammation
The adhesive qualities of arterial and venous endothelial
cells can be modified by inflammation or disease. In
comparison with the arterial environment, lower venous
shear stresses combined with increased venous endo-
thelial permeability and responsiveness (to at least some
inflammatory mediators) may make venules and veins
more susceptible to developing inflammation. For ex-
ample, Kalogeris et al., [13] showed that cytokine-
responsive endothelial cell adhesion molecule (ECAM)
responses toward cytokine exposure were higher in ven-
ous endothelium than in corresponding (umbilical) ar-
terial endothelium, and also supported higher (venous)
endothelial rates of binding of monocytes. Tumor necro-
sis factor (TNF)-α and lipopolysaccharide (LPS) were
seen to significantly increase monocyte binding to ven-
ous, but not arterial endothelium in vitro. Furthermore,
neither TNF-α nor LPS induced surface expression of
vascular cell adhesion molecule (VCAM)-1 or E-selectin
in arterial endothelium, and TNF did not induce
VCAM-1 mRNA in arterial endothelium. Lastly, as a
VLA-4 blocking antibody prevented about 75% of TNF-
α-stimulated monocyte adhesion in venous endothelium,
VCAM-1 dependent adhesion may be particularly im-
portant in TNF-α response. Interestingly, despite a TNF-
α-mediated increase in surface-expressed intercellular
adhesion molecule (ICAM)-1 in arterial endothelium,
TNF-α did not increase monocyte adhesion to arterial
endothelium. Amberger et al. [14] also found that
venous endothelium (umbilical and saphenous veins)
expressed higher levels of ICAM-1, VCAM-1, and E-
selectin than arterial endothelium in response to TNF-α,
interleukin (IL)-1β, and LPS, but lower levels of ad-
hesion molecule responses to low density lipoprotein.
Therefore, venous endothelium appears to be innately
programmed for higher adhesive responses compared
with arterial endothelium. Similarly, Wang and Feuerstein
[15] showed that ischemia is a potent, albeit slower stimu-
lus for ICAM-1 and E-selectin expression in the brain,
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NAWM with immune cell infiltration.
With respect to underlying BBB differences between
venous and arterial endothelium, we have previously
reported that, compared with arterial endothelial cells,
venous endothelial cells expressed more vascular endo-
thelial (VE)-cadherin at the mRNA and protein levels
Kevil et al., [16]. Conversely, arterial endothelial cells
were found to express eighteen-fold more occludin at
the protein and nine-fold more at the mRNA level.
Occludin was also seen to be more organized at inter-
endothelial junctions in umbilical arterial endothelial
cells compared with umbilical venous endothelial cells
Kevil et al., [16]. Interestingly, disturbances in flow dir-
ection, but not necessarily shear, modulate claudin-5, an-
other component of tight junctions, which also shows
arteriovenous endothelial heterogeneity, with arterial
endothelium expressing higher levels of claudin-5 than
venous endothelium [17]. Claudin-5 is also induced by
estradiol [18], which could be a factor in gender-specific
differences in BBB or disease incidence. Endothelial ex-
pression of junctional components (and barrier) also de-
pends on other cells in the neurovascular complex, such
as astrocytes [19], as well as the effects of inflamma-
tory mediators on these support cells and the endo-
thelium [20].
Although arterial and venous endothelial cells are het-
erogeneous, ‘arterialization’ of venous endothelial grafts
(for example, in coronary artery bypass grafts), also sug-
gests that fluid shear, oxygen tension differences, and
other environmental factors can remodel transplanted
veins into arterial homologs, and significant post-natal
arteriovenous plasticity may be induced under different
circumstances. Because each vascular type exhibits dif-
ferent relative responses to different types of injury and
inflammatory stimuli, chronically altered shear stress or
retrograde flow may lead to injury, which could reflect
the mechanical trauma of the intima, as well as a shear-
dependent remodeling of vessels exposed to shear forces.
Adamson et al. recently showed that retrograde flow,
rather than shear forces, diminishes the venous endo-
thelial solute barrier by decreasing the organization of
endothelial junctional VE-cadherin and occludin, a fin-
ding supporting the concept that abnormal flow patterns
can dysregulate endothelial barrier properties Adamson
et al., [21]. It is still unclear whether transvenular
leukocyte extravasation is also enhanced by retrograde
flow.
Zakkar et al. reported that induction of a pro-
inflammatory phenotype on venous endothelial cells in-
volves the phosphorylation-dependent activation of p38
mitogen-activated protein kinase (MAPK), which leads
to the production of chemokines, including IL-8 and
monocyte chemotactic protein-1 Zakkar et al., [22].Thus, veins exposed to shear undergo activation of p38
MAPK, which may lead to inflammation. By contrast,
shear exposure in arteries has been shown to lead to
induction of MAPK phosphatase (MKP)-1, which de-
creases MAPK signaling. In that report, Sakkar et al.
demonstrated that dexamethasone could induce expres-
sion of MKP-1 in venous endothelium, effectively recap-
itulating the protective effect of shear seen in arterial
endothelium exposed to laminar shear stress. These
events require extracellular regulated kinase (Erk)1 and
Erk 2, cAMP response element binding, and oxidant sig-
naling. The current use of dexamethasone in MS might
therefore correct an abnormal flow-mediated activation
of venous inflammatory programs and fully integrate
components of the BBB.
Is there altered hemodynamic signaling in venous
inflammation?
In what other ways might flow disturbances lead to
hyperactivation of inflammatory responses in the venous
circulation? Krueppel-like factor (KLF)2 and KLF4 are
shear-dependent transcription factors that suppress
endothelial responses to inflammatory stimuli, such as
TNF-α [23], and several important shear-sensing mecha-
nisms rely on KLF2 and KLF4 to provide important links
between laminar fluid shear and the maintenance of a
quiescent endothelial phenotype (Table 1). Conversely,
disturbances in normal flow patterns might increase
inflammation through KLF2/4 dysregulation. Laminar
shear regulates KLF2 by promoting the phosphorylation
and nuclear export of histone deacetylase (HDAC)5, a
process under the control of Ca2+/calmodulin. This pro-
cess partitions HDAC5 from myocyte enhancer factor-2,
which then triggers KLF2 expression. Wu et al., [24] also
showed that laminar shear suppressed miRNA-92a, an
endogenous inhibitor of KLF2 [24] and KLF4 [25]. KLF4
expression is also suppressed by HDACs, and is de-
repressed by the HDAC inhibitor trichostatin-A (Table 1)
[26]. KLF2 expression varies dramatically between ar-
teries and veins, with arteries expressing about four-fold
more KLF2 than their corresponding veins [23]. Liu
et al. also found that freshly isolated arterial endothe-
lium expressed higher levels of KLF2 than did venous
endothelium, consistent with greater KLF2 arterial re-
sponses to fluid shear stress [23]. KLF2 was shown to be
suppressed by inflammatory stimuli such as IL-1β [27],
unlike KLF4, which paradoxically was activated by TNF-
α, IL-1β and interferon (IFN)-γ [28], as well as shear.
Venous cells exposed to shear also increase KLF2 ex-
pression (compared with static cultures) [29]. KLF2 is an
important shear-activated transcription factor which
upregulates endothelial nitric oxide synthase (eNOS)
and thrombomodulin (TM) expression and reduces plas-
minogen activator inhibitor-1 (PAI-1) expression [30].
Table 1 Pathophysiology of venous abnormalities in multiple sclerosis and potential therapeutic strategies





Induction of MKP-1, protection







Activation of KLF2 and KLF4 Statin drugs, HDAC inhibitors
(for example, trichostatin-A)
[8,30,36,40]
BBB dysregulation NMDA receptor, MMP-8,
MMP-9, p38 MAPK
MMP inhibitor, p38 MAPK inhibitor Doxycycline, minocycline, SB 239063 [41-44]
Venous remodeling Collagens, iron, TGF-β1, p38
MAPK, VEGF, TIMP, MMP
p38 MAPK inhibitor, TGF modifier,
angiotensin antagonist, anti-







PGI2, NO, EDHF Venous pressure reduction venoplasty [48,49]
Abbreviations: BBB blood-brain barrier, CCSVI chronic cerebrospinal venous insufficiency, EDHF endothelium-derived hyperpolarizing factor, eNOS Endothelial nitric
oxide synthase, HDAC histone deacetylase, KLF Krueppel-like factor, MAPK mitogen-activated protein kinase, MKP mitogen-activated protein kinase phosphatase,
MMP matrix metalloproteinase, MS multiple sclerosis, NMDA N-methyl-D-aspartate, NO nitrous oxide, PAI plasminogen activator inhibitor, PGI2 prostaglandin I2
(prostacyclin), TGF transforming growth factor, TIMP tissue inhibitor of metalloproteinase, TNF tumor necrosis factor, VCAM vascular cell adhesion molecule, VEGF
Vascular endothelial growth factor.
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1 and E-selectin expression and TNF-α induction of tis-
sue factor (TF) [27,30,31]. Shear-induced expression of
KLF2 also suppresses activation of the pro-inflammatory
transcription factors activator protein-1, nuclear factor
κB Das et al., [32], and activating transcription factor 2
Fledderus et al., [33]. Importantly, induction of KLF2 in
venous endothelium reduced TNF-α-induced E-selectin
and VCAM-1. Shear-activated KLF2 also maintains
endothelial quiescence by suppression of TNF-α re-
ceptors, upregulation of eNOS [27] and by decreasing
angiopoietin-2 content in endothelial Weibel-Palade
bodies [34]. KLF4 is similarly induced in endothelial cells
by laminar shear stress and interestingly by inflamma-
tory cytokines. Like KLF2, KLF4 also induces eNOS and
TM, and suppresses endothelial VCAM-1 expression.
KLF4 activation also decreases thrombus formation by
downregulating tissue factor expression [28], and KLF4
also downregulates plasminogen activator inhibitor
(PAI)-1. Therefore venous hemodynamic flow distur-
bances that lead to silencing of anti-inflammatory
KLF2/KLF 4 programs might increase inflammation
through altered endothelial barrier, leukocyte binding,
and hemostasis [35]. Interestingly, 3-hydroxy-3-me-
thylglutaryl-coenzyme A reductase statin drugs have
recently been described as activators of KLF2 [36]
and KLF4 [37], and may restore or maintain athe-
roprotective programs suppressed by abnormal venous
flow fluid shear patterns. Statin activation of KLF2
also induces hemoxygenase-1, an important suppres-
sor of inflammation [38]. Similarly, other drugs that
maintain KLF2/4, such as HDAC inhibitors, might
represent novel treatments for treating abnormal sig-
naling in venous (and also arterial) endothelium pro-
duced by flow abnormalities.Is the blood-brain barrier altered by factors induced in
neurodegenerative disorders?
Several factors present in MS may dysregulate BBB in
such a way that when presented with altered flow or
pressure gradients, significant disturbances in BBB could
be produced. It is now fairly well accepted that VE cells
express N-methyl-D-aspartate (NMDA) and metabotro-
pic receptor complexes, which contribute to regulation
of the BBB. Glutamate is increased in the cerebrospinal
fluid (CSF) in patients during relapse [50] consistent
with its release during CNS injury. Binding of glutamate
to endothelial NMDA receptor elevates intracellular oxi-
dants [44] and disturbs the microvascular barrier [51],
effects that may exacerbate matrix metalloproteinase
(MMP)-9-mediated proteolysis of tight junctional com-
ponents in the BBB, such as occludin Wachtel et al., [52]
and claudin-5 [53]. Serum MMP-8 and MMP-9 are cor-
related with decreased numbers of T2-weighted lesions.
[41]It is unclear what the sources of these MMPs are in
this setting. Importantly, MMP-9 is known to proteolyze
occludin, a tight junction target of the BBB Wachtel
et al., [52]. Interestingly, it has been reported that, com-
pared with laminar shear stress, oscillatory flow in-
creases endothelial MMP-9 expression [54], and might
alter the BBB in regions experiencing abnormal flow. In
Alzheimer’s disease, β-amyloid appears to help activate
MMP-9, and may increase permeability [55]. Other pro-
teases, such as neutrophil elastase, may disturb the BBB
Carden et al., [56] and proteolyze VE-cadherin. In this
setting, generation of oxidants can inhibit endogenous
anti-proteases such as α-1 anti-trypsin [57] and tissue
inhibitors of metalloproteinase (TIMPs) [58], which limit
junction-degrading proteases, and thus exacerbate BBB
failure. The use of broad-spectrum antioxidants and
MMP inhibitors (such as doxycycline and minocycline)
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BBB. Several groups have described elevations of circu-
lating inflammatory cytokines (IL-12p40, IL-17, IL-23) in
patients with active MS, which decrease during remis-
sion or are reduced by IFN-β1b therapy [41]. Mechanis-
tically, factors in sera from MS patients (in exacerbation)
were found to decrease VE-cadherin and occludin ex-
pression [7], potentially contributing to the loss of BBB
integrity through weaker junction organization, protein
expression, and junction degradation.
Activation of p38 MAPK may influence the structural
integrity of the blood brain barrier and assembly of com-
ponents forming the BBB. For example, p38 MAPK acti-
vation has been shown to disturb normal assembly of
occludin within tight junctions [59]. Furthermore, ex-
posure of endothelial cells to the growth factor vascular
endothelial growth factor (VEGF)-A increases per-
meability through phosphorylation of serine occludin
(Ser490), which promotes the ubiquitination and clear-
ance of Ser90. This loss of occludin at junctions would
be expected to ‘disintegrate’ the normal junctional bar-
rier. Interestingly, another effect of dexamethasone in
‘arterializing’ venous endothelium appears to be its effect
in ‘externalizing’ cytoplasmic occludin [60], leading to a
denser junction organization (Table 1). Therefore, lam-
inar shear activation of p38 MAPK (in arterial en-
dothelium) might enhance junction assembly, while
conversely, venous shear might disassemble junctions. It
is possible that orally available p38 MAPK inhibitors,
(for example, SB 239063), might stabilize venous junc-
tions and limit vascular permeability.
MS and venous remodeling
In MS, ‘Dawson’s fingers’ are fine periventricular white
matter venous lesions that appear early on in the course
of MS, and are often arranged around the longitudinal
axis of the central veins [8]. The venous association of
this lesion has long been suspected to link venous
system disturbances with the etiology of MS [61-65].
This phenomenon may represent inflammation, shear-
mediated mechanical trauma, or disturbances in pres-
sure. Anatomic reports by Schelling suggested that these
lesions reflect ‘hemodynamic back jetting,’ which is theo-
rized to be an important cause of venous injury [29].
Such lesions may be correlated with restricted outflow,
which may caused by structural disturbances present in
MS veins Coen et al., [66]. These structural alterations
may involve switching from collagen type I to type III,
which may provoke other structural abnormalities, in-
cluding valve disturbances, which might alter venous
hemodynamics [49]. This type of matrix remodeling
might be adaptive in acute venous congestion to limit
hemorrhages and iron deposition; such changes in mat-
rix thickness or composition in ‘mature’ lesions couldlimit exchange or perfusion. Such non-inflammatory
wall thickening is normal during aging. It is unclear
whether venous structural or flow disturbances in MS
might represent part of a spectrum of venous diseases
seen outside of the CNS. The incidence of chronic ven-
ous disease outside of the CNS increases with age, al-
though the age of onset for MS is between the ages of
20 and 30 years, with a female preponderance [4,67].
Like chronic venous disease, MS also shows greater
prevalence in female and European populations. Inter-
estingly, CVI, which is characterized by weak flow of
venous blood, especially in the legs [68], is also charac-
terized by collagen isoform remodeling, but shows eleva-
tion of collagen type I expression and diminished type
III expression [46], increased fibrillin-1 and laminin, and
overproduction of MMP1, MMP2, and MMP3 [69].
Interestingly, transforming growth factor (TGF)β1 in-
duces endothelial apoptosis in a collagen-dependent
manner, with matrix collagen type I maintaining endo-
thelial viability despite exposure to TGF-β1 [70]. Con-
versely, endoglin appears to oppose TGF-β1 induced
collagen synthesis by p38 MAPK activation [71], and
was found to suppress TGF β1-induced collagen synthe-
sis when ERK1/2 signaling was present. The use of p38
MAPK inhibitors, such as dilmapimod [45], might help
to prevent TGF-β1-associated venous remodeling.
Both the elevation and suppression of TGF-β1 in
venous structure suggest a role for TGF-β1 in CVI
pathogenesis [72-75]. Active TGF-β1 increases inducible
nitric oxide synthase, which dysregulates venous tone
and blood flow [73]. CVI is associated with suppression
of the proliferative responses of fibroblasts and smooth
muscle cells to TGF-β1 [76]. TGF-β1 signaling in fibro-
blasts is mediated by ERK1/2 and SMAD activation
[76-78]. It is unclear whether TGF modifiers, such as
avotermin, might have clinical benefit in MS, as has
been suggested in CVI [47]. Similarly, the angiotensin II
receptor antagonist candesartan inhibits TGF-β1-in-
duced MMP9 via Smad7 Yu et al., [79], therefore, angio-
tensin antagonists may also be able to suppress the
vessel remodeling that can contribute to vascular abnor-
malities in MS.
Bevacizumab has been shown to diminish injury in the
experimental autoimmune encephalomyelitis model of
MS by suppressing angiogenesis, suggesting that VEGF
may play some part in the development of MS [80],
Argaw et al. suggested that astrocytes might represent
an important source of VEGF-A, which leads to the acti-
vation of eNOS and plays a significant role in the loss of
BBB that occurs in MS [42]. Although not yet tested, the
effects of VEGF-A on venous structure could lead to a
similar loss of BBB, leading to the extravasation of lym-
phocytes and plasma protein, which could provoke in-
jury and vessel remodeling. Therefore, anti-angiogenic
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applications in MS treatment (Table 1). Immunochemi-
cal and MRI methods have confirmed erythrocyte pene-
tration in a subset of MS lesions, and the accumulation
of iron-laden macrophages occurs predominantly around
venules, with venous vascular lesions regularly showing
iron signatures [81-85]. Iron released by extravasated
erythrocytes becomes susceptible to Fenton and Haber-
Weiss oxidant-generating reactions in the parenchyma,
mediated by reactive oxygen species, which leads to al-
terations in second messenger signaling and tissue injury
(Figure 1). Iron chelators (for example, desferrioxamine)
(Table 1) may be effective in lowering the overall iron
(and oxidant) burden.
Vessel structure in CVI is correlated with vessel stiff-
ening; a reversed collagen expression in MS might sug-
gest a hypercompliant venous structure. CVI is also
characterized by an higher TIMP-1/MMP-2 ratio, which
might favor deposition of non-elastic matrix [86]. We
reported previously that MS exhibits increased expres-
sion of MMP-8 and MMP-9, which was suppressed by
IFNβ1b therapy and was correlated with reduced T2-
weighted lesions [41]. We also reported that addition of
doxycycline, an MMP inhibitor similar to IFNβ1b, sig-
nificantly reduced contrast-enhancing lesion numbers
and disability scores. Lower serum MMP-9 levels corre-
lated with fewer contrast-enhancing lesions. Furthermore,
transendothelial migration of monocytes, stimulated byFigure 1 Venous endothelial injury in neuroinflammatory disease. Alt
valve failure lead to endothelial disturbances that provoke localized inflamm
demyelination and disability in MS. Flow sensors that may be dysregulated
eNOS, and blood-brain barrier function and iron deposition. Venous valve s
this schema include α9-integrin/fibronectin (FNIIIa), Ephrin B2/EphB4, FOXC
oxide synthase; FOXC2, Forkhead box protein C2; KLF, Krueppel-like factor;
sclerosis; NFATC1, nuclear factor of activated T-cells, cytoplasmic 1; VEGFR,MS serum, was reduced in patients undergoing combin-
ation therapy with doxycycline [43]. Like MS, CVI is also
characterized by increased circulating levels of MMP-9,
and MMP-1, MMP-2, and TIMP-1 were also reported to
be increased in CVI [Saito et al., 2001]. During chronic
venous disease, the venous valves and the vessel wall ex-
hibit monocyte and macrophage infiltration [87], which is
characterized by increased expression of ICAM-1 [88].
Importantly, Takase et al. found inflammation of the vasa
vasorum, which could provoke wall remodeling. Individ-
uals with CVI retain more leukocytes, in which may ex-
plain the greater quantities of circulating leukocytes in
CVI Bergan et al. [89]. Patients with CVI also have higher
leukocyte activation and oxidant production compared
with controls [90]. Powell et al. found more platelet-
monocyte aggregates in CVI (29% versus 8%; P < 0.0002),
while CD11b expression on monocytes in CVI was ap-
proximately twice that of controls (7.5 vs. 3.7; P<0.01).
The presence of CVI also led to greater generation of
platelet leukocyte aggregates [91]. Therefore, low or retro-
grade flow states, as may exist in CVI, might lead to a per-
ilous imbalance favoring vascular inflammatory programs.
Are there hemodynamic influences in venous vascular
disturbances?
Other forms of venous restriction may also contribute to
alterations in BBB. Early studies by Putnam using venous
obstruction showed development of MS-like lesionserations in normal flow induced by changes in outflow resistance or
atory responses, which may intensify immune activation, leading to
include MKP-1, KLF2, and KLF4, which control adhesion molecule,
tructural and regulatory components that might be dysregulated in
2/Prox1/NFATC1, and VEGFR-3. Abbreviations: eNOS, endothelial nitric
MKP, mitogen-activated protein kinase phosphatase; MS, multiple
vascular endothelial growth factor receptor.
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deliberate occlusion of the superior vena cava produced
vascular solute leakage, primarily in venules. We also
found recently that experimentally increased intra-
abdominal hypertension (IAH) in mice (produced by
abdominal volume), also caused a rapid and reversible
failure of BBB (as shown by extravasation of Evans blue
stain). Such changes are presumably hydrodynamic, be-
cause they resolved within 2 hours after relief of IAH
[94]. Clinically, IAH above 20 mm Hg diminished ven-
ous return, and translated into increased intracranial
pressure [95]. Interestingly, with respect to the potential
influence of altered hemodynamics and cyclical pressure
changes in the venous barrier, Shin et al. [96-99] showed
that cyclical pressure modulates venous endothelial pro-
liferative and barrier responses through mechanotrans-
duction-regulated changes in fibroblast growth factor
receptor/basic fibroblast growth factor and VEGF-C sig-
naling. Interestingly, cyclical high (but not low) pressure
disorganized tight (ZO-1) rather than adherens (VE-
cadherin) junctional organization , and this was associ-
ated with diminished blood brain barrier.These studies
provide mechanistic links between environmental pres-
sure changes and an ‘inflammatory’ venous phenotype. It
is not yet clear if such responses are unique to venous
(and not arterial) endothelium.
Interestingly, Miyamoto et al. [100] and Yura et al.
[101] showed that bilateral occlusion of the external
jugular veins, like in mice subjected to middle cerebral
artery occlusion, led to an increase in brain ischemia.
Therefore, if resistance to venous outflow, either pres-
sure-mediated or structurally mediated, provokes de-
creased cerebral blood flow as has been suggested
[8-10], such disturbances could trigger tissue injury and
demyelination (as seen in MS). An important question
remains as to how downstream restriction of venous
outflow might lead to a dysregulated vascular phenotype
upstream of the point of insufficient venous drainage.
Restriction to venous outflow would also be expected to
impair normal flow-mediated vasodilatation. Impaired
production of dilators such as prostacyclin, nitrous oxide,
and endothelium-derived hyperpolarizing factor would
lead to a retrograde volume/pressure transmission that
might present as venous vascular injury. Restriction of
venous outflow and congestion has been suggested to lead
to distention and remodeling of venous capillaries into
veins, which may have very differently structural and func-
tional properties. Venous congestion may also provoke
thrombus formation via both reduced flow and altered
endothelial surface properties.
Whether intracranial venous pressure (IVP) is in-
creased in MS remains highly controversial. McTaggart
et al. described significant internal jugular vein (IJV)
‘flattening’ in MS and a trend toward more non-IJVcollaterals [48]. Although increased intra-abdominal
pressure may be produced by venous obstruction or
jugular valve insufficiency, and might thenbe transmitted
to the intracranial venous system, causing intracranial
hypertension, [102], the significance of this mechanism
in chronic cerebrospinal venous insufficiency (CCSVI)
remains very controversial. Meyer-Schwickerath repor-
ted that venous pressures are normal in patients with
MS [103], as measured by ophthalmodynamometry.
Haacke et al. [2] pointed out that angioplasty in patients
with MS Zamboni et al., [104] reduced venous pressure,
consistent with relative pre-operative venous hyperten-
sion. Several recent reports have indicated that altered
craniocervical venous outflow may also be detected in
individuals diagnosed with chronic migraine [105,106],
suggesting that cranial venous outflow disturbances may
represent a ‘secondary’ rather than a primary pheno-
menon. Conversely, Lee et al. considered the ontogeny
of several venous malformations, as they may contribute
to flow disturbances in patients with MS, supporting the
idea of cerebrospinal venous malformations as a primary
event, which might lead to venous hypertension Lee
et al., [107]. Although abnormal venous flow patterns in
MS are being corrected through endovascular approaches,
future studies to correlate and validate clinical outcomes
and pathological mechanism are clearly needed.
Increased intracranial venous pressure without venous
leakage or demyelination: pseudotumor cerebri
Venous vascular leakage attributed to MS might be
explained intuitively as the result of increased IVP, al-
though this explanation has not been fully accepted. Of
relevance to this issue is the disorder pseudotumor
cerebri (PC) (also known as idiopathic intracranial hy-
pertension), in which prolonged and demonstrably high
intracranial pressures are not associated with venous
leakage or demyelination. PC belongs to a set of disor-
ders that include hydrocephalic states and spontaneous
(primary) intracranial hypotension, in which the CSF cir-
culation interfaces with the blood circulatory system.
CSF moves by bulk flow and pulsatile forces (transferred
from the cerebral arteries) from the ventricles into the
spinal and cortical subarachnoid spaces. CSF is then
largely absorbed via the arachnoid villi into the superior
sagittal sinus (SSS). The pressure of the CSF (intracranial
pressure, ICP) must always exceed blood pressure in the
SSS for this absorption to take place. With reversal of
this gradient, such as in newborns with stenosis of the
jugular foramina, hydrocephalus results, as the unfused
cranial sutures allow for an expansion of the ventricles,
which are accumulating CSF [108]. With sutures closed,
a fully myelinated, healthy brain will resist ventricular
expansion, although ICP will rise, a condition predispo-
sing to PC.
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with the greatest incidence in the young adult years
[109]. It is characterized by high ICP, papilledema, head-
ache, visual blurring and loss, tinnitus, retrobulbar pain,
and neck stiffness [110]. Ventricular size is normal or
slightly reduced. In most cases, dural venous sinus out-
flow obstructions or increased right atrial pressures raise
IVP to the point where it challenges the ICP [111].
The MRI diagnosis of PC is partly one of exclusion of
other causes of increased ICP, such as choroid plexus
papilloma, cerebral edema, tumor, and obstructive hy-
drocephalus. Positive signs of intracranial hypertension
include empty sella, bilateral increased fluid in the optic
sheath, mild flattening of the posterior sclera, enhance-
ment of the prelaminar optic nerve, distension of the
periotic subarachnoid space, vertical tortuosity of the
optic nerve, and gadolinium enhancement of the prela-
minar optic nerve [112].
Absent from these patients are the MRI hyperintensity
signals indicating demyelination. In the study of Wall
et al., microscopic examination of brain tissue from pa-
tients with PC at autopsy showed no neuronal necrosis,
gliosis, or inflammation, and no prominence of perivas-
cular spaces or pallor of myelin in neuropil or white
matter [113]. Although these findings do not exclude
endothelial injury, the absence of inflammation and de-
myelination under conditions of prolonged venous hy-
pertension points to the existence of factors that may
protect these patients from demyelinating disease. Ex-
perimental studies focusing on high ICP states, as found
in PC, would help identify these factors.
Genes regulating venous valves
At the molecular level, if congenital or pathologic al-
terations in venous valve structure contribute to the
etiology of CVI and other venous disturbances [114],
identifying genes that control venous valve structure
might provide important clues to the basis of venous
pathology Bazigou et al. [115,116] described that venous
valves are organized by interactions of several genes at
different developmental stages and post-natally. The
development of venous valves requires signaling from
Prospero-related homeobox 1 (Prox1), vascular endothe-
lial growth factor receptor (VEGFR)-3, and integrin α9.
The binding of integrin α9 to fibronectin-IIIa is also an
important structural motif necessary for venous/lymph-
atic valve assembly [115]. Lymphatic valve formation
also involves Cnb1/NFATc1, connexin 37 and 43, and
laminin-a5. Nuclear factor of activated T-cells, cytoplas-
mic 1 (NFATc1) also modulates cardiac valve formation
[117]. The later maturation of these valves also requires
Sema3A/Neuropilin-1/PlexinA1 signaling Bouvrée et al.
[3]. Interestingly, Ephrin-B2 and integrin α9 were both
shown to be necessary for maintenance of venous valves,as post-natal editing of these genes induced valve atresia
[116]. Further, integrin α9, VEGFR3, and Prox1 were
also found to be expressed in lymphatic vessel valves.
Additional regulators of venous and lymphatic valve
structure may include the Tie2 receptor tyrosine kinase
and multiple angiopoietin ligands [116]. Tie2 signaling
also appears to be responsive to altered patterns of fluid
shear and is dysregulated by abnormal flow. Flow may
also influence valve structure/function, as eNOS levels
within valve endothelium are increased [118], and eNOS
expression appears to modulate valve development, at
least in aortic valves [119].
Forkhead box protein C2 (FOXC2) is another tran-
scription factor expressed in venous and lymphatic
valves, which controls their development Mellor et al.,
[120]. FOXC2 is dysregulated in lymphedema distichiasis
[121]. Mellor et al. showed that individuals exhibiting
mutations in FOXC2 uniformly exhibited valve distur-
bances in the saphenous and deep veins, contributing to
venous reflux and lymphedema Mellor et al., [120]. Inter-
estingly, although FOXC2 gene mutations were closely
associated with venous valve failure and were seen in
carriers, these individuals did not have lymphedema. Cur-
rently, it is still unclear whether ‘silent’ alterations in ven-
ous/lymphatic programming genes such as FOXC2 might
contribute to venous valve failure in CNS pathology.
Among these regulators, Ephrin-B2 is usually con-
sidered to be an arterial and lymphatic specific family
transmembrane ligand that binds the receptor tyrosine
kinase EphB4, and participates in venous specification
[122,123]. EphA2 and ephrinA1 are both persistently
expressed by cultured brain endothelial cells, and treat-
ment of brain endothelial cells with inflammatory cyto-
kines caused the shedding of these markers into brain
endothelial derived microparticles, which are small
(<0.1 μm) plasma membrane vesicles [124]. Similarly,
samples of control and MS serum showed increased
levels of ephrin A1 and EphA2 expression in vessel
structures in MS brain tissue [125]. Several vascular
ephrins and Eph receptors may therefore be dysregu-
lated in CNS inflammation, although not all of them
have an influence on vascular remodeling. In the setting
of CVI, IJV incompetence has been correlated with
transient global amnesia [107,126-129], which may con-
tribute to cognitive disturbances in several neurodegen-
erative conditions. Ephrin-B2 is strongly expressed in
venous endothelium, and suppresses endothelial prolifer-
ative responses towards VEGF and Ang-2 Kim et al.,
[130]. By comparison, the receptors EphB2 and EphB3 are
strongly expressed by arterial endothelium, and EphB/
ephrin-B interactions have been suggested to modulate ar-
teriovenous specification and separation. It is interesting
to note that during inflammation, endothelial expression
of EphA2 receptor and ephrin-B2 is increased [131].
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We have previously examined genes that were modified
in cerebrovascular endothelial cells in response to serum
from patients with RRMS, and found several markers
that were modulated by soluble factors present in
MS serum and by IFN-β1b therapy, including 14-3-3,
metavinculin, myosin-3, plasminogen, reticulocalbin-2
and eticulocalbin--3, ribonuclease/angiogenin inhibitor,
annexin A1, tropomyosin, and Rap1A [5]. Ferlini et al.
(performed a gene array on chromosome 6p21.32
(human leukocyte antigen (HLA) locus) in patients ex-
hibiting venous malformations associated with MS, and
found several candidate genes that were altered inclu-
ding heat shock protein (HSP)A1L, HSPA1A, metabo-
tropic glutamate receptor (GRM)4, and growth factor
receptor-bound protein 2, an adaptor involved in MAPK
signaling Ferlini et al., [132]. Pirmohamed et al, showed
that HSPA1L might be linked with HLA-associated drug
hypersensitivity [133], and increased GRM4 has also
been reported in MS lesions [134]. Several genes that are
associated with MS and inflammatory disease progres-
sion (VEGF, endothelin-1, IL-6, VCAM-1, ICAM-1,
MMP-2, MMP-9 and PAI-1) are also modulated by al-
terations in mechanical stretch on the vessel wall [135].
Therefore, genes that drive venous disturbances might
reflect the coincident presence of both heritable and en-
vironmental (shear/stretch) risk factors.
Optic neuritis and vascular endothelial injury
Optic neuritis (ON) an inflammatory demyelinating dis-
ease of the optic nerve, is a common early feature of
MS, and often leads to some degree of visual loss in pa-
tients. Inflammatory demyelination of the optic nerve in
ON can histopathologically resemble acute MS plaques
in the brain. For example, ON shows nerve sheath ede-
ma, perivenous ‘cuffing’, destruction of myelin, and vas-
cular fluorescein leakage. Retinal VE inflammation
usually precedes demyelination, and is often detected as
retinal vein ‘sheathing’ [136]. Papillitis (inflammation of
the optic nerve head), with increased blood flow and ret-
inal edema, blurring of disk margins, and swollen veins
can be seen in up to 30% of patients presenting with
ON. A significant number of patients with ON have ret-
robulbar neuritis, and present with abnormal fundus-
copic findings.
An interesting finding in patients with MS is focal
sheathing of the retinal veins (periphlebitis retinae),
which includes local perivenous infiltration of lympho-
cytes and plasma cells [137,138], post-inflammatory
peri-venular gliosis [137], and evidence of focal extrava-
sation of plasma proteins [137]. Although the human
retina has limited myelin and myelin basic proteins
(limited by the lamina cribrosa [139]), or myelinating ol-
igodendrocytes, it is still unclear as to why some patientswith MS patients periphlebitis retinae. One theory to ex-
plain such findings is that other myelin-associated anti-
gens, such as, the human natural killer-1 carbohydrate
epitope and myelin-associated glycoprotein, can be
expressed by retinal Müller glial cells [140,141]. How-
ever, this hypothesis cannot sufficiently explain the ret-
inal findings in MS. To consider this issue, Engell et al.
[142] investigated retinal venous alterations in patients
with acute ON. MS was found in 41 of 76 patients ex-
amined for ophthalmologic issues; 1 patient had peri-
phlebitis retinae and two had venous ‘sheathing’. It was
concluded that altered venous structure in the retina in-
dicated an ultimate diagnosis of MS. Therefore, because
retinal venous abnormalities in patients with MS occur
outside the key areas of demyelination, perivenular in-
flammation may represent the early event contributing
to new lesions. Perivenous sheathing (periphlebitis ret-
inae) indicates some loss of normal blood-retinal barrier.
Therefore, sheathing may most be often perivenular be-
cause the venous endothelial junctions are inherently
less restrictive than those of the corresponding arterial
endothelium. The increased venous tendency to express
adhesive inflammation-associated ECAMs in response to
inflammatory or hypoxic stimuli, along with immune cell
retention, may initiate or sustain exaggerated responses.
In retinal endothelial monolayers (which exhibit BBB
properties,) we found that the junctional solute barrier
required actin microfilament assembly, was positively
regulated by β-adrenoreceptor signaling [143], and was
dysregulated by increased glucose levels [144]. There-
fore, the BBB may be dysregulated by changes in circu-
lating autacoids or metabolic disturbances.
Developmental venous anomalies
Haacke et al. [2] suggested that that venous hyperten-
sion caused by congenital or pathologic changes could
provoke the development of dural arteriovenous struc-
tural abnormalities in MS. It has even been suggested
[145]that the presence of congenital venous anomalies
may occur in some isolated populations (such as in
Sardinia) that could contribute to more frequent or
earlier-onset venous disturbances. It has been proposed
that more profound vascular flow disturbances in these
populations might provoke neurovascular forms of in-
jury, which could include CCSVI or MS [145]. It is un-
clear whether additional risk factors are necessary to
increase the penetrance of this phenotype and appea-
rance of this condition.
Pathophysiology of ADEM, with emphasis on venous
dysfunction
ADEM is a relatively rare CNS inflammatory demyeli-
nating disease, which affects both adults and children.
ADEM typically occurs as a single-stage syndrome. It is
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vaccination encephalomyelitis’), and may also occur after
some systemic viral infections (for example, measles).
Clinically, ADEM produces a variety of symptoms, in-
cluding fever, headache, meningismus, seizures, loss of
sensation/tingling, visual loss, weakness or paralysis, loss
of coordination, involuntary spasms, and loss of sphinc-
ter control. Neuropathologically, ADEM exhibits scat-
tered focal demyelination, which is usually limited to the
perivenous areas. The underlying neuropathological de-
fects in ADEM can affect both the brain and spinal cord,
with MRI often revealing large and diffuse or multifocal
lesions. This appearance differs from that of MS in that
MS lesions are focal, smaller, and confluent [146]. The
MRI lesions of ADEM involve both gray and white
matter [147].
Neuropathological studies in ADEM have shown
merged regions of perivenular demyelination throughout
the cerebral hemispheres, brainstem, cerebellum, and
spinal cord. Although these lesions are usually most nu-
merous in the white matter, they can affect deeper layers
of the cerebral cortex, thalamus, hypothalamus, and
other gray-matter areas within the brain. Microscopic-
ally, ADEM affects small distended veins enclosed within
parenchymal infiltrates of reactive microglia, lympho-
cytes, macrophages, and occasionally neutrophils, associ-
ated with demyelination [39].
Although the details of ADEM pathogenesis remain
only partially understood, interactions between inflamed
and activated underlying cerebral venous endothelium
and activated leukocytes play major roles in its develop-
ment. Following activation of the immune system, either
because of molecular mimicry or sensitization against
the self-antigens following a viral infection, myelin basic
protein-reactive lymphocytes can interact with the ven-
ous endothelium [148]. Such interactions between the
inflamed venous endothelium and the activated leuko-
cytes can disrupt the normal functional and anatomical
integrity of the cerebral venous endothelium, and even-
tually promote the transendothelial migration of leuko-
cytes and release of neuroinflammatory mediators such
as cytokines and chemokines. Further research into the
immunopathogenesis of ADEM versus MS reveals that
T helper (Th)1-related and Th2-related chemokines are
generated during both ADEM and MS. ADEM shows
upregulation of chemokines for neutrophils (CXCL1,
CXCL7), monocytes/T cells (CCL3, CCL5), Th1 cells
(CXCL10), and Th2 cells (CCL1, CCL22, and CCL17)
[39]. Further, the involvement of MMP-9 [149] and in-
creased serum levels of soluble ICAM-1 in the patho-
genesis of ADEM has been shown [150], which places
more emphasis on endothelial disturbances underlying
ADEM pathology. Interestingly, the inflammatory de-
myelinating lesions of ADEM do not form near arterialvessels. This finding itself lends support to the concept
that inherent venous (rather than arterial) endothelial
anatomic or functional abnormalities drives ADEM.Conclusions
The roles of anatomical and functional abnormalities of
the cerebral venous endothelium in the pathogenesis of
human CNS inflammatory diseases such as MS and
ADEM often remain unrecognized, underinvestigated,
and untreated. Rather than these diseases simply being
the result of structural disturbances of veins, together
with the combined hemodynamic (low/abnormal flow,
pressure/congestion), programmatic (arterial, venous,
valvular) and environmental (metabolic, hypoxic) stres-
ses to which venous endothelial cells are exposed may
render them particularly susceptible to inflammatory
activation, contributing to several neurovascular path-
ologies. Presently, markers of arterial and venous endo-
thelial specification and the role of each cell type in
inflammation are now receiving more attention. A more
thorough understanding of such mechanisms based on
the developmental, cellular, and molecular mechanisms
underlying the hemodynamic disturbances of these con-
ditions will open many new therapeutic targets for de-
bilitating diseases such as Alzheimer’s disease and MS.
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